Boyce, Sara http://orcid.org/0000-0002-0671-3269
Fletcher, Simon
Jones, April
Kohli, Ruchika http://orcid.org/0000-0002-8683-326X
Mangles, Sarah
Ong, Min
Pollard, Debra
Sivasubramaniyam, Sujan http://orcid.org/0000-0002-0859-0370
Stephensen, David
Stoner, Nicola http://orcid.org/0000-0001-8132-7475
Kazmi, Rashid
Funding for this research was provided by:
CSL Behring
Article History
Received: 20 April 2023
Accepted: 18 November 2023
First Online: 25 November 2023
Declarations
:
: Not applicable.
: Not applicable.
: All authors received funding from CSL Behring for medical writing support for the present manuscript. SB has received grants or contracts for research support from Sangamo Therapeutics; consultancy fees from CSL Behring for an advisory board; payment or honoraria from Alexion Pharmaceuticals for a presentation; and support from Sanofi to attend the International Society on Thrombosis and Haemostasis congress. SF has received an unrestricted educational grant from uniQure; consultancy fees from CSL Behring for an advisory board and from BioMarin Pharmaceutical for production of patient education materials; speaker fees from Amgen; support from Sanofi to attend the International Society on Thrombosis and Haemostasis congress; and has participated in the National Haemophilia Database Adverse Events group and was previously chairman of the Haemophilia Nurses Association. AJ has received consultancy fees, payment or honoraria, and travel fees from CSL Behring for advisory boards; and speaker fees from Novo Nordisk. RKa has received consultancy fees from Norgine; sponsorship from CSL Behring and Novo Nordisk for attending meetings; and payments from CSL Behring and BioMarin Pharmaceutical for advisory board participation. SM has received payment or honoraria for lectures, presentations, speaking, or educational events from Sobi, Roche, and Novo Nordisk; has participated in advisory boards for Takeda Pharmaceutical, Roche, Chugai Pharmaceutical, CSL Behring, Novo Nordisk, Sobi, and Sanofi; and has received support for attending meetings from Octapharma, Roche, and Novo Nordisk. MO has received consultancy/honorarium fees from CSL Behring for participation in an advisory board; consultancy fees from Roche, CSL Behring, Novartis, and Biogen; honoraria as neuromuscular masterclass faculty and consultancy fees from the Neurology Academy; speaker fees from Biogen for a British Paediatric Neurology Association symposium; sponsorship from Roche and PTC Therapeutics to attend the European Paediatric Neurology Society conference; is a member of the national UK multidisciplinary team for spinal muscular atrophy gene therapy and is a steering committee member for the UK Spinal Muscular Atrophy Newborn Screening Alliance, and the Spinal Muscular Atrophy Research and Clinical Hub UK. DP has received consultancy fees for advisory boards regarding educational materials from BioMarin Pharmaceutical, CSL Behring, Freeline Therapeutics, Pfizer, and Chugai Pharmaceutical, and for advisory boards supporting staff development from Sobi and Chugai Pharmaceutical; payment or honoraria for presentations or speakers bureaus from Novo Nordisk, Chugai Pharmaceutical, Sobi, Sanofi, and Takeda Pharmaceutical; and is a voluntary member of the Haemophilia Nurses Association UK Committee, European Haemophilia Consortium Medical and Scientific Advisory Group, and the European Haemophilia Consortium Think Tank Council. DS has received a research grant from the National Institute for Health and Care Research and unrestricted research grants from Bayer, Roche, and the European Association for Haemophilia and Allied Disorders; and speaker honoraria from Sanofi and Sobi. NS has received consultancy fees from CSL Behring for an advisory board and honoraria from Astellas Pharma for an educational event. SS and RKo are full-time employees of CSL Behring.